Loading…
← CockpitCompetitor Analysis › 002658.SZ Beijing SDL Technology Co., Ltd. Class AOpen in the cockpit ↗

Beijing SDL Technology Co., Ltd. Class A002658.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum neutral 52
Mkt cap
$864M
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$4.03M
20-day average traded
Fwd P/E
22.4×
forward earnings
ROIC−WACC
+2.0 pp
WACC 8.4%
Hurdle
+14 pp
Req g minus delivered
Next earnings
128 days
26 Mar 2027
Close · CNYCN¥6.60
1D-1.5%
1W-4.1%
1M-4.6%
3M-11.8%
6M-34.4%
YTD-26.9%
1Y-21.7%
ATR %3.0%
52w lowhigh44.1% off high

What Beijing SDL Technology does

Employees: 1,484

Beijing SDL Technology at a glance

Size Beijing SDL Technology (002658.SZ) is a China Health Care company (Medical Specialties) with a market value of $864M, the 2446th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.60 on 18 Nov 2026.

Performance Over six months the shares fell 34.4%, against -15.1% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue fell 13.4% over the last twelve months (peer median +10.4%); the operating margin is 8.9% (peer median 10.0%).

Valuation It trades at 22.4× forward earnings against a peer median of 26.0× (7th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.0 points above its cost of capital (8.4% WACC).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 85002658.SZ 66
Six months, rebased to 100: Beijing SDL Technology against the median of its 20 peers (local-currency closes).

Beijing SDL Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.27BCN¥1.39BCN¥1.41BCN¥1.50BCN¥1.50B
Revenue growth—-2%-6%0%—
Gross profitCN¥569MCN¥568MCN¥556MCN¥583MCN¥658M
EBITDAn/aCN¥217MCN¥202MCN¥217MCN¥311M
Net incomeCN¥137MCN¥151MCN¥169MCN¥203MCN¥284M
Free cash flowCN¥222MCN¥233MCN¥233MCN¥320MCN¥208M
Capital expenditureCN¥120MCN¥78.2MCN¥29.8MCN¥29.1MCN¥35.9M
Total debtCN¥3.65MCN¥8.13MCN¥7.39MCN¥19.4MCN¥306M

Quarterly statements and history in the cockpit →

Beijing SDL Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%68865630160268827768862668876768857536006033671187BVSKIDSAORT688805688068MCAPAMS096530290650002658.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Beijing SDL Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×68865668862668876768857536006033673015801187BVSAORTKURNAMS096530002658.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beijing SDL Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%68865630160268857536006033673015801187BVS688805MCAPAMS096530290650002658.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Beijing SDL Technology is the large dot.

Beijing SDL Technology competitors and peer comparison

How Beijing SDL Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing SDL Technology against its 20 peers (data as of 18 Nov 2026)
Measure002658.SZPeer medianRank in peer set
1-month return-4.6%-8.4%7th highest of 21
6-month return-34.4%-15.1%6th lowest of 21
Distance from 52-week high-44.1%-41.9%10th lowest of 21
Revenue growth (TTM)-13.4%+10.4%lowest of 21
Operating margin8.9%10.0%10th lowest of 21
Forward P/E22.4×26.0×7th cheapest of 15
Growth the price implies (Req g, 7 yrs)16.8%7.5%6th most demanding of 14
Growth delivered (Del g)+2.9%+12.4%3rd lowest of 14
Hurdle (Req g minus delivered)+13.9 pp-4.0 pp3rd most demanding of 14
ROIC minus cost of capital+2.0 pp+1.5 pp11th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Beijing SDL Technology 002658.SZChina$864M-34%-13%9%22.4×16.8%+2.9%
HOB Biotech 688656.SSChina$858M-33%+6%7%166.9×37.6%+12.4%
Shantou Institute of Ultrasonic Instruments 301602.SZChina$858M-25%+4%30%n/a11.1%+4.6%
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%n/an/an/a
Xiangyu Medical 688626.SSChina$877M-38%0%4%56.2×n/an/a
Hangzhou Biotest Biotech 688767.SSChina$878M-12%-4%3%37.0×n/an/a
Shenzhen YHLO Biotech 688575.SSChina$882M-16%+3%12%30.7×2.0%+12.7%
Modern Dental 3600.HKHong Kong$844M+24%+12%22%8.5×-7.1%+11.3%
Cisen Pharmaceutical 603367.SSChina$843M-15%-6%8%7.9×-14.6%-1.3%
Aidite (Qinhuangdao) Technology 301580.SZChina$888M-12%+17%18%26.2×19.3%+23.3%
Cofoe Medical Technology 1187.HKHong Kong$836M-11%+40%10%13.1×-6.4%+6.6%
Bioventus BVSUnited States$895M-3%+4%10%13.0×7.5%+12.1%
OrthoPediatrics KIDSUnited States$826M+71%+16%-8%n/an/an/a
Artivion AORTUnited States$905M-18%+14%5%383.6×n/an/a
Kuros Biosciences KURN.SWSwitzerland$907M-12%+41%6%70.5×n/an/a
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%n/a35.6%+17.1%
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%n/an/an/a
MedCap MCAP.STSweden$811M-4%+17%15%25.8×2.7%+20.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%20.7×20.0%+21.4%
Seegene 096530.KSSouth Korea$808M-26%+13%13%20.0×-6.7%-15.9%
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%n/a32.6%+21.0%

Questions

Which companies are Beijing SDL Technology's closest peers?
The cockpit's peer set: HOB Biotech (688656.SS), Shantou Institute of Ultrasonic Instruments (301602.SZ), Tinavi Medical Technologies (688277.SS), Xiangyu Medical (688626.SS), Hangzhou Biotest Biotech (688767.SS), Shenzhen YHLO Biotech (688575.SS), Modern Dental (3600.HK), Cisen Pharmaceutical (603367.SS).
Is Beijing SDL Technology expensive compared with its peers?
On forward p/e it trades at 22.4× against a peer median of 26.0×, 7th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Beijing SDL Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -34.4% against -15.1% for the median peer; over one year -21.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.